A Phase II Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in Metastatic Treatment naïve Pancreas Adenocarcinoma
Summary
The purpose of this phase II study is to evaluate the safety and efficacy of CXCR4 antagonist (motixafortide), (cemiplimab), gemcitabine and nab-paclitaxel in patients with pancreatic adenocarcinoma.
General Information
NCT#: NCT04543071
Study ID: AAAS9513
Trial Phase: Phase II
Trial Sponsor: Regeneron Pharmaceuticals, Gulam Manji, BioLine Rx
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Cemiplimab, Motixafortide (BL-8040)